Reports and Briefs on Cardiovascular and Diabetes in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | » »|

Type Product title / description Pub Price
Report
Report

The Dyslipidemia Market Outlook to 2021

In the wake of Lipitor’s patent expiry, the dyslipidemia market continues to face increasing genericization leading to falling sales in key drug classes.

Published By Datamonitor
04 Feb 2013 $4500
Buy
Report
Report

Hemophilia Pipeline Overview – Once-a-week prophylaxis may soon become a reality

Datamonitor provides an overview of and profiles key hemophilia A and B pipeline products launching in the near future in the US and five major EU markets (France, Germany, Italy, Spain, and the UK).

Published By Datamonitor
12 Nov 2012 $3800
Buy
Report
Report

Product Profiles: Stroke Prevention in Atrial Fibrillation – Uptake slower than expected for the first warfarin alternatives, the novel oral anticoagulants

This report provides analysis of key oral anticoagulants brands and pipeline agents for stroke prevention in atrial fibrillation (SPAF) across the seven major markets, including a comparative evaluation of clinical and commercial drug attributes.

Published By Datamonitor
22 Aug 2012 $11400
Buy
Report
Report

Product Profiles: Non-Insulin Antidiabetics – Options abound as the SGLT-2 class prepares for market entry

Datamonitor profiles leading, currently marketed non-insulin brands as well as pipeline products launching in the near future. Coverage: the US, Japan, France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
14 Aug 2012 $7600
Buy
Report
Report

Market and Product Forecasts: Non-Insulin Antidiabetics – Incretin mimetics face off in type 2 diabetes

Datamonitor patient-based forecast of leading non-insulin brands and pipeline products for 2011 to 2020. Coverage: US, Japan, France, Germany, Italy, Spain, and the UK.

Published By Datamonitor
29 May 2012 $11400
Buy
Report
Report

Epidemiology: Stroke – Aging global population leads to more incident cases of stroke

Overview of stroke and atrial fibrillation definitions and a review of the epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year incident case forecast, and key patient segments in the seven major markets.

Published By Datamonitor
17 May 2012 $3800
Buy
Report
Report

Treatment Algorithms: Dyslipidemia – Statin monotherapies dominate the market but uncontrolled lipid levels remain an issue

This report provides detailed dyslipidemia treatment paths based on a survey of 125 primary care physicians across the seven major markets, with analysis of patient potential, patient segments, prescribing patterns, and leading treatment regimens.

Published By Datamonitor
08 May 2012 $7600
Buy
Report
Report

Product Profiles: Insulin Antidiabetics – Key developers compete for basal insulins market

In-depth analysis of key insulin brands and pipeline agents indicated for the treatment of type 1 and type 2 diabetes. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
27 Apr 2012 $7600
Buy
Report
Report

Treatment Algorithms: Hypertension – Multiclass combinations are common but preferences differ by market

This report provides detailed hypertension treatment paths based on a survey of 153 primary care physicians across the seven major markets, with analysis of patient potential, patient segments, prescribing patterns, and leading treatment regimens.

Published By Datamonitor
27 Mar 2012 $7600
Buy
Report
Report

Epidemiology: Dyslipidemia – Undertreated and underdiagnosed pandemic

Overview of dyslipidemia definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year prevalent forecast, and key patient segments across an emerging market.

Published By Datamonitor
22 Feb 2012 $5700
Buy

« | 1 | 2 | 3 | 4 | » »|

No help is available.